Monty Pal, MD

Dr. Pal is co-director of the Kidney Cancer Program at City of Hope and head of the kidney and bladder cancer disease team at the institution.

Articles by Monty Pal, MD

Monty Pal, MDASCO GU Symposium 2024 | February 6, 2024
CheckMate 9ER, 67T and KEYNOTE-564 are discussed.
View More
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 18, 2023
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Monty Pal, MDUromigos Live 2023 | November 8, 2023
Dr. Monty Pal discusses the current IO-refractory RCC space and approaches to patients in the 2nd- and 3rd-line settings.
Brian Rini, MD, FASCOVideo Insights | March 22, 2023
In the final segment of a debate series, Brian Rini, MD, and Monty Pal, MD, debate RCC adjuvant therapeutic options.
Monty Pal, MDRoundtable | March 15, 2023
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
Monty Pal, MDRoundtable | August 23, 2023
The panel shares how they treat frontline papillary kidney cancer.
Brian Rini, MD, FASCOVideo Insights | March 16, 2023
In the second segment of a debate series, Drs. Rini and Pal address kidney cancer clinical trials of interest.
Monty Pal, MDRoundtable | March 15, 2023
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
Brian Rini, MD, FASCOVideo Insights | March 15, 2023
In a debate series between Brian Rini, MD, and Monty Pal, MD, they discuss frontline RCC treatment options.
Monty Pal, MDRoundtable | June 20, 2023
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
Monty Pal, MDRoundtable | April 26, 2023
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
Monty Pal, MDRoundtable | April 10, 2023
The panel discusses outcomes from the CheckMate-9ER trial and addresses the importance depth of response.
Monty Pal, MDRoundtable | March 31, 2023
The panel compares three TKI/IO treatment combinations.
Monty Pal, MDRoundtable | March 14, 2023
The panel discusses considerations for treatment choice in patients with poor- and intermediate-risk disease.
Monty Pal, MDRoundtable | March 14, 2023
A panel discusses 4 frontline RCC treatment options.